JP2011516558A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011516558A5 JP2011516558A5 JP2011504114A JP2011504114A JP2011516558A5 JP 2011516558 A5 JP2011516558 A5 JP 2011516558A5 JP 2011504114 A JP2011504114 A JP 2011504114A JP 2011504114 A JP2011504114 A JP 2011504114A JP 2011516558 A5 JP2011516558 A5 JP 2011516558A5
- Authority
- JP
- Japan
- Prior art keywords
- piperazinyl
- pyrimidine
- spiro
- alkylene
- amine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 35
- 125000002947 alkylene group Chemical group 0.000 claims 29
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 125000000623 heterocyclic group Chemical group 0.000 claims 9
- ZSWFCLXCOIISFI-UHFFFAOYSA-N cyclopentadiene Chemical compound C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 7
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- -1 diastereomers Chemical class 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims 5
- 150000001721 carbon Chemical group 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 5
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 claims 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 5
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 5
- 125000002883 imidazolyl group Chemical group 0.000 claims 5
- 125000002971 oxazolyl group Chemical group 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000004193 piperazinyl group Chemical group 0.000 claims 5
- 125000003386 piperidinyl group Chemical group 0.000 claims 5
- 125000003373 pyrazinyl group Chemical group 0.000 claims 5
- 125000002098 pyridazinyl group Chemical group 0.000 claims 5
- 125000004076 pyridyl group Chemical group 0.000 claims 5
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 5
- 125000000168 pyrrolyl group Chemical group 0.000 claims 5
- 125000000335 thiazolyl group Chemical group 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- JWOHGGWZVXDGKE-UHFFFAOYSA-N n-[6-[4-(dimethylamino)piperidin-1-yl]pyridin-3-yl]-6,6-dimethylspiro[cyclohexene-3,9'-pyrido[4,5]cyclopenta[1,2-d]pyrimidine]-2'-amine Chemical compound C1CC(N(C)C)CCN1C(N=C1)=CC=C1NC1=NC=C(C=2C(=CN=CC=2)C23C=CC(C)(C)CC3)C2=N1 JWOHGGWZVXDGKE-UHFFFAOYSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000003003 spiro group Chemical group 0.000 claims 2
- UZMQNDXJBUGQGR-AREMUKBSSA-N (4r)-2,2-dimethyl-n-(4-piperazin-1-ylphenyl)spiro[oxane-4,5'-pyrido[4,5]pyrano[1,2-d]pyrimidine]-3'-amine Chemical compound C1COC(C)(C)C[C@]21C1=NC(NC=3C=CC(=CC=3)N3CCNCC3)=NC=C1C1=CC=CN=C1O2 UZMQNDXJBUGQGR-AREMUKBSSA-N 0.000 claims 1
- UZMQNDXJBUGQGR-SANMLTNESA-N (4s)-2,2-dimethyl-n-(4-piperazin-1-ylphenyl)spiro[oxane-4,5'-pyrido[4,5]pyrano[1,2-d]pyrimidine]-3'-amine Chemical compound C1COC(C)(C)C[C@@]21C1=NC(NC=3C=CC(=CC=3)N3CCNCC3)=NC=C1C1=CC=CN=C1O2 UZMQNDXJBUGQGR-SANMLTNESA-N 0.000 claims 1
- XPAQCWJQFDUFRG-UHFFFAOYSA-N 1'-methyl-n-[4-(4-methylpiperazin-1-yl)phenyl]spiro[indeno[2,1-d]pyrimidine-9,4'-piperidine]-2-amine Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C(C=2C(=CC=CC=2)C23CCN(C)CC3)C2=N1 XPAQCWJQFDUFRG-UHFFFAOYSA-N 0.000 claims 1
- CNSRBQCJNXYMLH-UHFFFAOYSA-N 1,1-dimethyl-n-(5-piperazin-1-ylpyridin-2-yl)spiro[cyclohexane-4,5'-pyrido[4,5]pyrano[1,2-d]pyrimidine]-3'-amine Chemical compound C1CC(C)(C)CCC21C1=NC(NC=3N=CC(=CC=3)N3CCNCC3)=NC=C1C1=CC=CN=C1O2 CNSRBQCJNXYMLH-UHFFFAOYSA-N 0.000 claims 1
- VKQXFISZNCIIPG-UHFFFAOYSA-N 1,1-dimethyl-n-(6-piperazin-1-ylpyridin-3-yl)spiro[cyclohexane-4,5'-pyrido[4,5]pyrano[1,2-d]pyrimidine]-3'-amine Chemical compound C1CC(C)(C)CCC21C1=NC(NC=3C=NC(=CC=3)N3CCNCC3)=NC=C1C1=CC=CN=C1O2 VKQXFISZNCIIPG-UHFFFAOYSA-N 0.000 claims 1
- UZMQNDXJBUGQGR-UHFFFAOYSA-N 2,2-dimethyl-n-(4-piperazin-1-ylphenyl)spiro[oxane-4,5'-pyrido[4,5]pyrano[1,2-d]pyrimidine]-3'-amine Chemical compound C1COC(C)(C)CC21C1=NC(NC=3C=CC(=CC=3)N3CCNCC3)=NC=C1C1=CC=CN=C1O2 UZMQNDXJBUGQGR-UHFFFAOYSA-N 0.000 claims 1
- IBRCIRUFQOJXNZ-UHFFFAOYSA-N 2-(4-piperazin-1-ylanilino)spiro[6h-pyrrolo[3,4-d]pyrimidine-7,1'-cycloheptane]-5-one Chemical compound C12=NC(NC=3C=CC(=CC=3)N3CCNCC3)=NC=C2C(=O)NC21CCCCCC2 IBRCIRUFQOJXNZ-UHFFFAOYSA-N 0.000 claims 1
- RAUKUSHQQZGEEB-UHFFFAOYSA-N 2-(4-piperazin-1-ylanilino)spiro[6h-pyrrolo[3,4-d]pyrimidine-7,1'-cyclohexane]-5-one Chemical compound C12=NC(NC=3C=CC(=CC=3)N3CCNCC3)=NC=C2C(=O)NC21CCCCC2 RAUKUSHQQZGEEB-UHFFFAOYSA-N 0.000 claims 1
- YIWVUGXZQFJCKX-UHFFFAOYSA-N 2-(4-piperazin-1-ylanilino)spiro[6h-pyrrolo[3,4-d]pyrimidine-7,1'-cyclopentane]-5-one Chemical compound C12=NC(NC=3C=CC(=CC=3)N3CCNCC3)=NC=C2C(=O)NC21CCCC2 YIWVUGXZQFJCKX-UHFFFAOYSA-N 0.000 claims 1
- XSGYMNQFEOGOMJ-UHFFFAOYSA-N 2-[4-(4-methylpiperazin-1-yl)anilino]spiro[6h-pyrrolo[3,4-d]pyrimidine-7,1'-cyclohexane]-5-one Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C(C(=O)NC23CCCCC3)C2=N1 XSGYMNQFEOGOMJ-UHFFFAOYSA-N 0.000 claims 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 claims 1
- VVXCEQMAKYLXNK-UHFFFAOYSA-N 3'-[(5-piperazin-1-ylpyridin-2-yl)amino]spiro[cyclohexane-4,5'-pyrido[4,5]pyrano[1,2-d]pyrimidine]-1-ol Chemical compound C1CC(O)CCC21C1=NC(NC=3N=CC(=CC=3)N3CCNCC3)=NC=C1C1=CC=CN=C1O2 VVXCEQMAKYLXNK-UHFFFAOYSA-N 0.000 claims 1
- UKRNUFJCRZLYBC-UHFFFAOYSA-N 3-[(5-piperazin-1-ylpyridin-2-yl)amino]spiro[chromeno[3,4-d]pyrimidine-5,1'-cyclohexane]-7-carbonitrile Chemical compound N#CC1=CC=CC(C2=CN=C(NC=3N=CC(=CC=3)N3CCNCC3)N=C22)=C1OC12CCCCC1 UKRNUFJCRZLYBC-UHFFFAOYSA-N 0.000 claims 1
- SBOMELLQHJRNSW-UHFFFAOYSA-N 4,4-difluoro-n-(5-piperazin-1-ylpyridin-2-yl)spiro[cyclohexane-1,5'-pyrido[4,5]pyrano[1,2-d]pyrimidine]-3'-amine Chemical compound C1CC(F)(F)CCC21C1=NC(NC=3N=CC(=CC=3)N3CCNCC3)=NC=C1C1=CC=CN=C1O2 SBOMELLQHJRNSW-UHFFFAOYSA-N 0.000 claims 1
- SWIJTIWQYNFTBM-UHFFFAOYSA-N 5'-methyl-2'-[(5-piperazin-1-ylpyridin-2-yl)amino]spiro[cyclopentane-1,8'-quinazoline]-7'-one Chemical compound C12=NC(NC=3N=CC(=CC=3)N3CCNCC3)=NC=C2C(C)=CC(=O)C21CCCC2 SWIJTIWQYNFTBM-UHFFFAOYSA-N 0.000 claims 1
- MWTYHSLKLDNBBZ-UHFFFAOYSA-N 5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]spiro[5,6-dihydroquinazoline-8,4'-cyclopentene]-7-one Chemical compound C12=NC(NC=3N=CC(=CC=3)N3CCNCC3)=NC=C2C(C)CC(=O)C21CC=CC2 MWTYHSLKLDNBBZ-UHFFFAOYSA-N 0.000 claims 1
- XOEGISZWMOBKHL-UHFFFAOYSA-N 5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]spiro[6,7-dihydro-5h-quinazoline-8,1'-cyclopentane]-7-ol Chemical compound C12=NC(NC=3N=CC(=CC=3)N3CCNCC3)=NC=C2C(C)CC(O)C21CCCC2 XOEGISZWMOBKHL-UHFFFAOYSA-N 0.000 claims 1
- YWHKOEZHEOTZPZ-UHFFFAOYSA-N 5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]spiro[6,7-dihydro-5h-quinazoline-8,4'-cyclopentene]-7-ol Chemical compound C12=NC(NC=3N=CC(=CC=3)N3CCNCC3)=NC=C2C(C)CC(O)C21CC=CC2 YWHKOEZHEOTZPZ-UHFFFAOYSA-N 0.000 claims 1
- BCMALGYLQMMZKE-UHFFFAOYSA-N 6,6-dimethyl-n-(4-piperazin-1-ylphenyl)spiro[cyclohexene-3,9'-pyrido[4,5]cyclopenta[1,2-d]pyrimidine]-2'-amine Chemical compound C1=CC(C)(C)CCC21C1=NC(NC=3C=CC(=CC=3)N3CCNCC3)=NC=C1C1=CC=NC=C12 BCMALGYLQMMZKE-UHFFFAOYSA-N 0.000 claims 1
- JSQWLDVGNRBXGT-UHFFFAOYSA-N 6,6-dimethyl-n-(5-piperazin-1-ylpyridin-2-yl)spiro[cyclohexene-3,9'-pyrido[4,5]cyclopenta[1,2-d]pyrimidine]-2'-amine Chemical compound C1=CC(C)(C)CCC21C1=NC(NC=3N=CC(=CC=3)N3CCNCC3)=NC=C1C1=CC=NC=C12 JSQWLDVGNRBXGT-UHFFFAOYSA-N 0.000 claims 1
- PXZHKPVIQILAKW-UHFFFAOYSA-N 6,6-dimethyl-n-[6-(4-methylpiperazin-1-yl)pyridin-3-yl]spiro[cyclohexene-3,9'-pyrido[4,5]cyclopenta[1,2-d]pyrimidine]-2'-amine Chemical compound C1CN(C)CCN1C(N=C1)=CC=C1NC1=NC=C(C=2C(=CN=CC=2)C23C=CC(C)(C)CC3)C2=N1 PXZHKPVIQILAKW-UHFFFAOYSA-N 0.000 claims 1
- VXENGFFESGAOFS-UHFFFAOYSA-N 7,7-dimethyl-n-(4-piperazin-1-ylphenyl)-5,6-dihydrocyclopenta[d]pyrimidin-2-amine Chemical compound N1=C2C(C)(C)CCC2=CN=C1NC(C=C1)=CC=C1N1CCNCC1 VXENGFFESGAOFS-UHFFFAOYSA-N 0.000 claims 1
- VIGKNLNXPXDLFR-UHFFFAOYSA-N 7-fluoro-n-(4-piperazin-1-ylphenyl)spiro[chromeno[3,4-d]pyrimidine-5,1'-cyclohexane]-3-amine Chemical compound FC1=CC=CC(C2=CN=C(NC=3C=CC(=CC=3)N3CCNCC3)N=C22)=C1OC12CCCCC1 VIGKNLNXPXDLFR-UHFFFAOYSA-N 0.000 claims 1
- XTSLKLUDVUHHNZ-UHFFFAOYSA-N 7-fluoro-n-(4-piperazin-1-ylphenyl)spiro[chromeno[3,4-d]pyrimidine-5,4'-oxane]-3-amine Chemical compound FC1=CC=CC(C2=CN=C(NC=3C=CC(=CC=3)N3CCNCC3)N=C22)=C1OC12CCOCC1 XTSLKLUDVUHHNZ-UHFFFAOYSA-N 0.000 claims 1
- NEDQOLGOHNRKTJ-UHFFFAOYSA-N 7-fluoro-n-(5-piperazin-1-ylpyridin-2-yl)spiro[chromeno[3,4-d]pyrimidine-5,1'-cyclohexane]-3-amine Chemical compound FC1=CC=CC(C2=CN=C(NC=3N=CC(=CC=3)N3CCNCC3)N=C22)=C1OC12CCCCC1 NEDQOLGOHNRKTJ-UHFFFAOYSA-N 0.000 claims 1
- PXUISTCKLMIIBO-UHFFFAOYSA-N 7-methylsulfonyl-n-(5-piperazin-1-ylpyridin-2-yl)spiro[chromeno[3,4-d]pyrimidine-5,1'-cyclohexane]-3-amine Chemical compound CS(=O)(=O)C1=CC=CC(C2=CN=C(NC=3N=CC(=CC=3)N3CCNCC3)N=C22)=C1OC12CCCCC1 PXUISTCKLMIIBO-UHFFFAOYSA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- MNRNLELEHAIVAG-UHFFFAOYSA-N 9,9-diethyl-n-(5-piperazin-1-ylpyridin-2-yl)pyrido[4,5]cyclopenta[1,2-d]pyrimidin-2-amine Chemical compound N1=C2C(CC)(CC)C3=CN=CC=C3C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 MNRNLELEHAIVAG-UHFFFAOYSA-N 0.000 claims 1
- VOYMJQMEQSHQNF-UHFFFAOYSA-N C12=NC(N)=NC=C2C2=CC=CN=C2OC1(CC1)CCC21OCCO2 Chemical compound C12=NC(N)=NC=C2C2=CC=CN=C2OC1(CC1)CCC21OCCO2 VOYMJQMEQSHQNF-UHFFFAOYSA-N 0.000 claims 1
- UEWYRELXNLHLNX-KNBSFFNGSA-N C1[C@@H](C)N[C@@H](C)CN1C1=NC=CC=C1C1C2(C3=NC(N)=NC=C3C3=CC=NC=C32)C=CCC1 Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=NC=CC=C1C1C2(C3=NC(N)=NC=C3C3=CC=NC=C32)C=CCC1 UEWYRELXNLHLNX-KNBSFFNGSA-N 0.000 claims 1
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- WWUAGYOXKOQRIU-UHFFFAOYSA-N [3-[4-(4-methylpiperazin-1-yl)anilino]spiro[chromeno[3,4-d]pyrimidine-5,4'-piperidine]-1'-yl]-phenylmethanone Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C(C=2C(=CC=CC=2)OC23CCN(CC3)C(=O)C=3C=CC=CC=3)C2=N1 WWUAGYOXKOQRIU-UHFFFAOYSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 229940124452 immunizing agent Drugs 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- RVUSMBDDJZRKSD-UHFFFAOYSA-N n-(2-piperazin-1-ylpyrimidin-5-yl)spiro[chromeno[3,4-d]pyrimidine-5,4'-oxane]-3-amine Chemical class C1CNCCN1C(N=C1)=NC=C1NC1=NC=C(C=2C(=CC=CC=2)OC23CCOCC3)C2=N1 RVUSMBDDJZRKSD-UHFFFAOYSA-N 0.000 claims 1
- ASADGIQCNZJGEI-UHFFFAOYSA-N n-(4-morpholin-4-ylphenyl)spiro[indeno[2,1-d]pyrimidine-9,4'-piperidine]-2-amine Chemical compound C1CNCCC21C1=NC(NC=3C=CC(=CC=3)N3CCOCC3)=NC=C1C1=CC=CC=C12 ASADGIQCNZJGEI-UHFFFAOYSA-N 0.000 claims 1
- GPNCHAIPUWFBTF-UHFFFAOYSA-N n-(4-piperazin-1-ylphenyl)spiro[chromeno[3,4-d]pyrimidine-5,1'-cyclobutane]-3-amine Chemical compound C1CCC21C1=NC(NC=3C=CC(=CC=3)N3CCNCC3)=NC=C1C1=CC=CC=C1O2 GPNCHAIPUWFBTF-UHFFFAOYSA-N 0.000 claims 1
- VACDZZNBZFTEDK-UHFFFAOYSA-N n-(4-piperazin-1-ylphenyl)spiro[chromeno[3,4-d]pyrimidine-5,1'-cyclohexane]-3-amine Chemical compound C1CCCCC21C1=NC(NC=3C=CC(=CC=3)N3CCNCC3)=NC=C1C1=CC=CC=C1O2 VACDZZNBZFTEDK-UHFFFAOYSA-N 0.000 claims 1
- ALUSCKNZIZOCPD-UHFFFAOYSA-N n-(4-piperazin-1-ylphenyl)spiro[chromeno[3,4-d]pyrimidine-5,1'-cyclopentane]-3-amine Chemical compound C1CCCC21C1=NC(NC=3C=CC(=CC=3)N3CCNCC3)=NC=C1C1=CC=CC=C1O2 ALUSCKNZIZOCPD-UHFFFAOYSA-N 0.000 claims 1
- HFUXZQLGBZXVKA-UHFFFAOYSA-N n-(4-piperazin-1-ylphenyl)spiro[chromeno[3,4-d]pyrimidine-5,4'-oxane]-3-amine Chemical compound C1CNCCN1C(C=C1)=CC=C1NC1=NC=C(C=2C(=CC=CC=2)OC23CCOCC3)C2=N1 HFUXZQLGBZXVKA-UHFFFAOYSA-N 0.000 claims 1
- NDWBITNDLJOFGE-UHFFFAOYSA-N n-(4-piperazin-1-ylphenyl)spiro[cyclohexane-1,5'-pyrido[4,5]pyrano[1,2-d]pyrimidine]-3'-amine Chemical compound C1CCCCC21C1=NC(NC=3C=CC(=CC=3)N3CCNCC3)=NC=C1C1=CC=CN=C1O2 NDWBITNDLJOFGE-UHFFFAOYSA-N 0.000 claims 1
- PODFSHPTZVABJF-UHFFFAOYSA-N n-(4-piperazin-1-ylphenyl)spiro[cyclohexane-1,9'-indeno[2,1-d]pyrimidine]-2'-amine Chemical compound C1CCCCC21C1=NC(NC=3C=CC(=CC=3)N3CCNCC3)=NC=C1C1=CC=CC=C12 PODFSHPTZVABJF-UHFFFAOYSA-N 0.000 claims 1
- AUGLRFXMHWXOGR-UHFFFAOYSA-N n-(4-piperazin-1-ylphenyl)spiro[indeno[2,1-d]pyrimidine-9,4'-oxane]-2-amine Chemical compound C1CNCCN1C(C=C1)=CC=C1NC1=NC=C(C=2C(=CC=CC=2)C23CCOCC3)C2=N1 AUGLRFXMHWXOGR-UHFFFAOYSA-N 0.000 claims 1
- SPCHTHPFSHHDSL-UHFFFAOYSA-N n-(4-piperazin-1-ylphenyl)spiro[indeno[2,1-d]pyrimidine-9,4'-piperidine]-2-amine Chemical compound C1CNCCN1C(C=C1)=CC=C1NC1=NC=C(C=2C(=CC=CC=2)C23CCNCC3)C2=N1 SPCHTHPFSHHDSL-UHFFFAOYSA-N 0.000 claims 1
- PSQHUJNAOWDFNJ-UHFFFAOYSA-N n-(4-piperazin-1-ylphenyl)spiro[oxane-4,5'-pyrido[4,5]pyrano[1,2-d]pyrimidine]-3'-amine Chemical compound C1CNCCN1C(C=C1)=CC=C1NC1=NC=C(C=2C(=NC=CC=2)OC23CCOCC3)C2=N1 PSQHUJNAOWDFNJ-UHFFFAOYSA-N 0.000 claims 1
- UWVZXQFYSXOSHR-UHFFFAOYSA-N n-(4-piperazin-1-ylphenyl)spiro[oxane-4,6'-pyrido[4,5]pyrano[1,2-d]pyrimidine]-8'-amine Chemical compound C1CNCCN1C(C=C1)=CC=C1NC1=NC=C(C=2C(=CC=CN=2)OC23CCOCC3)C2=N1 UWVZXQFYSXOSHR-UHFFFAOYSA-N 0.000 claims 1
- OITDRNKBTIKEPD-UHFFFAOYSA-N n-(4-piperidin-1-ylphenyl)spiro[indeno[2,1-d]pyrimidine-9,4'-piperidine]-2-amine Chemical compound C1CCCCN1C(C=C1)=CC=C1NC1=NC=C(C=2C(=CC=CC=2)C23CCNCC3)C2=N1 OITDRNKBTIKEPD-UHFFFAOYSA-N 0.000 claims 1
- BGVTYYHETSUAHF-UHFFFAOYSA-N n-(5-piperazin-1-ylpyridin-2-yl)spiro[chromeno[3,4-d]pyrimidine-5,1'-cyclohexane]-3-amine Chemical compound C1CCCCC21C1=NC(NC=3N=CC(=CC=3)N3CCNCC3)=NC=C1C1=CC=CC=C1O2 BGVTYYHETSUAHF-UHFFFAOYSA-N 0.000 claims 1
- YGFSJFCRMXWQKO-UHFFFAOYSA-N n-(5-piperazin-1-ylpyridin-2-yl)spiro[chromeno[3,4-d]pyrimidine-5,1'-cyclopentane]-3-amine Chemical compound C1CCCC21C1=NC(NC=3N=CC(=CC=3)N3CCNCC3)=NC=C1C1=CC=CC=C1O2 YGFSJFCRMXWQKO-UHFFFAOYSA-N 0.000 claims 1
- RIHZHKPKEOFIDE-UHFFFAOYSA-N n-(5-piperazin-1-ylpyridin-2-yl)spiro[chromeno[3,4-d]pyrimidine-5,4'-oxane]-3-amine Chemical class C1CNCCN1C(C=N1)=CC=C1NC1=NC=C(C=2C(=CC=CC=2)OC23CCOCC3)C2=N1 RIHZHKPKEOFIDE-UHFFFAOYSA-N 0.000 claims 1
- IFMBQNRYIYAPEC-UHFFFAOYSA-N n-(5-piperazin-1-ylpyridin-2-yl)spiro[cycloheptane-1,9'-pyrido[4,5]cyclopenta[1,2-d]pyrimidine]-2'-amine Chemical class C1CNCCN1C(C=N1)=CC=C1NC1=NC=C(C=2C(=CN=CC=2)C23CCCCCC3)C2=N1 IFMBQNRYIYAPEC-UHFFFAOYSA-N 0.000 claims 1
- ASHUZSZPWBHDTL-UHFFFAOYSA-N n-(5-piperazin-1-ylpyridin-2-yl)spiro[cyclohexane-1,5'-pyrido[4,5]pyrano[1,2-d]pyrimidine]-3'-amine Chemical class C1CCCCC21C1=NC(NC=3N=CC(=CC=3)N3CCNCC3)=NC=C1C1=CC=CN=C1O2 ASHUZSZPWBHDTL-UHFFFAOYSA-N 0.000 claims 1
- CDLARILBYBZFKT-UHFFFAOYSA-N n-(5-piperazin-1-ylpyridin-2-yl)spiro[cyclohexane-1,9'-pyrido[4,5]cyclopenta[1,2-d]pyrimidine]-2'-amine Chemical class C1CCCCC21C1=NC(NC=3N=CC(=CC=3)N3CCNCC3)=NC=C1C1=CC=NC=C12 CDLARILBYBZFKT-UHFFFAOYSA-N 0.000 claims 1
- APSVEQFRBIZXFT-UHFFFAOYSA-N n-(5-piperazin-1-ylpyridin-2-yl)spiro[cyclopentane-1,9'-pyrido[4,5]cyclopenta[1,2-d]pyrimidine]-2'-amine Chemical class C1CCCC21C1=NC(NC=3N=CC(=CC=3)N3CCNCC3)=NC=C1C1=CC=NC=C12 APSVEQFRBIZXFT-UHFFFAOYSA-N 0.000 claims 1
- NONOTKDJRFPWOF-UHFFFAOYSA-N n-(5-piperazin-1-ylpyridin-2-yl)spiro[oxane-4,9'-pyrido[4,5]cyclopenta[1,2-d]pyrimidine]-2'-amine Chemical compound C1CNCCN1C(C=N1)=CC=C1NC1=NC=C(C=2C(=CN=CC=2)C23CCOCC3)C2=N1 NONOTKDJRFPWOF-UHFFFAOYSA-N 0.000 claims 1
- XNIJPSILEGOMER-UHFFFAOYSA-N n-(6-piperazin-1-ylpyridin-3-yl)spiro[chromeno[3,4-d]pyrimidine-5,4'-oxane]-3-amine Chemical class C1CNCCN1C(N=C1)=CC=C1NC1=NC=C(C=2C(=CC=CC=2)OC23CCOCC3)C2=N1 XNIJPSILEGOMER-UHFFFAOYSA-N 0.000 claims 1
- WJEONZHMSHFHLX-UHFFFAOYSA-N n-(6-piperazin-1-ylpyridin-3-yl)spiro[cyclohexane-1,5'-pyrido[4,5]pyrano[1,2-d]pyrimidine]-3'-amine Chemical class C1CCCCC21C1=NC(NC=3C=NC(=CC=3)N3CCNCC3)=NC=C1C1=CC=CN=C1O2 WJEONZHMSHFHLX-UHFFFAOYSA-N 0.000 claims 1
- GVBMIVMMTLFMLJ-UHFFFAOYSA-N n-(6-piperazin-1-ylpyridin-3-yl)spiro[cyclohexane-1,9'-pyrido[4,5]cyclopenta[1,2-d]pyrimidine]-2'-amine Chemical class C1CCCCC21C1=NC(NC=3C=NC(=CC=3)N3CCNCC3)=NC=C1C1=CC=NC=C12 GVBMIVMMTLFMLJ-UHFFFAOYSA-N 0.000 claims 1
- NMFHKFFKELOMCN-UHFFFAOYSA-N n-[3-fluoro-4-(4-methylpiperazin-1-yl)phenyl]spiro[indeno[2,1-d]pyrimidine-9,4'-oxane]-2-amine Chemical compound C1CN(C)CCN1C(C(=C1)F)=CC=C1NC1=NC=C(C=2C(=CC=CC=2)C23CCOCC3)C2=N1 NMFHKFFKELOMCN-UHFFFAOYSA-N 0.000 claims 1
- KIUVKRAYAWQFTJ-UHFFFAOYSA-N n-[4-(4-methylpiperazin-1-yl)phenyl]spiro[chromeno[3,4-d]pyrimidine-5,1'-cyclohexane]-3-amine Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C(C=2C(=CC=CC=2)OC23CCCCC3)C2=N1 KIUVKRAYAWQFTJ-UHFFFAOYSA-N 0.000 claims 1
- JNFIJATUZBROAO-UHFFFAOYSA-N n-[4-(4-methylpiperazin-1-yl)phenyl]spiro[chromeno[3,4-d]pyrimidine-5,4'-piperidine]-3-amine Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C(C=2C(=CC=CC=2)OC23CCNCC3)C2=N1 JNFIJATUZBROAO-UHFFFAOYSA-N 0.000 claims 1
- IYHZQGGRKKZYFQ-UHFFFAOYSA-N n-[4-(4-methylpiperazin-1-yl)phenyl]spiro[indeno[2,1-d]pyrimidine-9,4'-oxane]-2-amine Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C(C=2C(=CC=CC=2)C23CCOCC3)C2=N1 IYHZQGGRKKZYFQ-UHFFFAOYSA-N 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- NZWIVEHQUGNXSA-UHFFFAOYSA-N piperazin-1-yl-[2-(spiro[cyclohexane-1,9'-pyrido[4,5]cyclopenta[1,2-d]pyrimidine]-2'-ylamino)-1,3-thiazol-4-yl]methanone Chemical compound C=1SC(NC=2N=C3C4(CCCCC4)C4=CN=CC=C4C3=CN=2)=NC=1C(=O)N1CCNCC1 NZWIVEHQUGNXSA-UHFFFAOYSA-N 0.000 claims 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- XJTSDJYRBOYQCI-UHFFFAOYSA-N tert-butyl 4-[4-(spiro[cyclohexane-1,9'-indeno[2,1-d]pyrimidine]-2'-ylamino)phenyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C(C=C1)=CC=C1NC1=NC=C(C=2C(=CC=CC=2)C23CCCCC3)C2=N1 XJTSDJYRBOYQCI-UHFFFAOYSA-N 0.000 claims 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims 1
- 229930192474 thiophene Natural products 0.000 claims 1
- 150000003852 triazoles Chemical class 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12327908P | 2008-04-07 | 2008-04-07 | |
| US61/123,279 | 2008-04-07 | ||
| PCT/US2009/039678 WO2009126584A1 (en) | 2008-04-07 | 2009-04-06 | Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011516558A JP2011516558A (ja) | 2011-05-26 |
| JP2011516558A5 true JP2011516558A5 (cg-RX-API-DMAC7.html) | 2012-05-24 |
| JP5530422B2 JP5530422B2 (ja) | 2014-06-25 |
Family
ID=40905030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011504114A Expired - Fee Related JP5530422B2 (ja) | 2008-04-07 | 2009-04-06 | 細胞周期阻害薬としてのｇｅｍ−二置換およびスピロ環式アミノピリジン／ピリミジン |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8389533B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2278973B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5530422B2 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE531372T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009233951B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2719538C (cg-RX-API-DMAC7.html) |
| MX (1) | MX2010010975A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009126584A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| WO2012129344A1 (en) | 2011-03-23 | 2012-09-27 | Amgen Inc. | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
| WO2013049250A1 (en) | 2011-09-27 | 2013-04-04 | Amgen Inc. | Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer |
| BR112014030812B1 (pt) | 2012-06-13 | 2022-11-08 | Incyte Holdings Corporation | Compostos tricíclicos substituídos como inibidores de fgfr, seus usos, composição farmacêutica e método para inibir uma enzima fgfr |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| WO2014109858A1 (en) | 2013-01-14 | 2014-07-17 | Amgen Inc. | Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture |
| JP6417338B2 (ja) | 2013-02-19 | 2018-11-07 | アムジエン・インコーポレーテツド | 癌の治療のためのｍｄｍ２阻害剤としてのシス−モルホリノン及び他の化合物 |
| US9758495B2 (en) | 2013-03-14 | 2017-09-12 | Amgen Inc. | Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer |
| ME03015B (me) | 2013-04-19 | 2018-10-20 | Incyte Holdings Corp | Biciklični heterocikli kao fgfr inhibitori |
| KR102305351B1 (ko) | 2013-11-11 | 2021-09-24 | 암젠 인크 | 암의 치료를 위한, mdm2 억제제 및 하나 이상의 추가적 약제학적 활성 제제를 포함하는 조합 요법 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| CR20170390A (es) | 2015-02-20 | 2017-10-23 | Incyte Holdings Corp | Heterociclos biciclicos como inhibidores de fgfr |
| HUE057838T2 (hu) | 2016-06-07 | 2022-06-28 | Jacobio Pharmaceuticals Co Ltd | SHP2 inhibitorokként hasznos új heterociklusos származékok |
| AU2017374721B2 (en) | 2016-12-16 | 2021-02-25 | Cstone Pharmaceuticals | CDK4/6 inhibitor |
| SMT202400385T1 (it) | 2017-03-23 | 2024-11-15 | Jacobio Pharmaceuticals Co Ltd | Nuovi derivati eterociclici utili come inibitori di shp2 |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| TWI782056B (zh) * | 2017-07-14 | 2022-11-01 | 日商鹽野義製藥股份有限公司 | 具有ｍｇａｔ２抑制活性的縮合環衍生物 |
| JP7150823B2 (ja) | 2017-09-08 | 2022-10-11 | アムジエン・インコーポレーテツド | ＫＲａｓ Ｇ１２Ｃの阻害剤及びそれを使用する方法 |
| TW201946630A (zh) | 2018-05-04 | 2019-12-16 | 美商英塞特公司 | Fgfr抑制劑之鹽 |
| SG11202010636VA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Solid forms of an fgfr inhibitor and processes for preparing the same |
| MA52501A (fr) | 2018-05-04 | 2021-03-10 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
| US11285156B2 (en) | 2018-06-12 | 2022-03-29 | Amgen Inc. | Substituted piperazines as KRAS G12C inhibitors |
| US20210393623A1 (en) | 2018-09-26 | 2021-12-23 | Jacobio Pharmaceuticals Co., Ltd. | Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| US12227509B2 (en) | 2019-01-11 | 2025-02-18 | Shionogi & Co., Ltd. | Dihydropyrazolopyrazinone derivative having MGAT2 inhibitory activity |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| PH12021552922A1 (en) | 2019-05-21 | 2022-04-04 | Amgen Inc | Solid state forms |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US20240139193A1 (en) | 2019-10-15 | 2024-05-02 | Amgen Inc. | Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| AU2020395185A1 (en) | 2019-12-04 | 2022-06-02 | Incyte Corporation | Derivatives of an FGFR inhibitor |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| CN110787163B (zh) * | 2019-12-05 | 2020-06-02 | 河北医科大学第二医院 | 一种用于神经保护和促进神经再生的药物组合物及其制剂 |
| US20230028414A1 (en) | 2019-12-16 | 2023-01-26 | Amgen Inc. | Dosing regimen of kras g12c inhibitor |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CN113880809B (zh) | 2020-07-03 | 2022-10-18 | 盛世泰科生物医药技术(苏州)有限公司 | 一种嘧啶类衍生物及其制备方法和应用 |
| KR20220021651A (ko) | 2020-08-14 | 2022-02-22 | 롬엔드하스전자재료코리아유한회사 | 유기 전계 발광 화합물, 복수 종의 호스트 재료 및 이를 포함하는 유기 전계 발광 소자 |
| CN116018334A (zh) | 2020-09-01 | 2023-04-25 | 弗门尼舍有限公司 | 制备3-(环己-1-烯-1-基)丙醛衍生物的方法 |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| CA3220155A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| TW202313611A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1168290A (en) | 1964-08-27 | 1969-10-22 | Allen & Hanburys Ltd | Novel Heterocyclic Compounds |
| IT1153216B (it) | 1981-10-16 | 1987-01-14 | Schering Ag | Procedimento per la preparazione di composti cianoeterociclici |
| US6498163B1 (en) | 1997-02-05 | 2002-12-24 | Warner-Lambert Company | Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
| CA2386955A1 (en) * | 1999-11-22 | 2001-05-31 | Warner-Lambert Company | Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes |
| CA2401368A1 (en) | 2000-03-06 | 2001-09-27 | Warner-Lambert Company | 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors |
| YU65502A (sh) | 2000-03-15 | 2005-11-28 | Aventis Pharma Deutschland Gmbh. | Supstituisani beta-karbolini sa ikb-kinaza inhibirajućim dejstvom |
| GB0007371D0 (en) | 2000-03-28 | 2000-05-17 | Astrazeneca Uk Ltd | Chemical compounds |
| ATE276257T1 (de) | 2000-06-30 | 2004-10-15 | Banyu Pharma Co Ltd | Pyrazinonderivate |
| WO2002042303A2 (en) * | 2000-10-31 | 2002-05-30 | Aventis Pharmaceuticals Inc. | Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents |
| WO2002076396A2 (en) * | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| KR100669578B1 (ko) | 2002-01-22 | 2007-01-15 | 워너-램버트 캄파니 엘엘씨 | 2-(피리딘-2-일아미노)-피리도[2,3-ｄ]피리미딘-7-온 |
| WO2003062246A1 (en) | 2002-01-22 | 2003-07-31 | Warner-Lambert Company Llc | 2-thia-1,6,8-triaza-naphtalene-2,2-dioxides as cdk inhibitors |
| US20030199525A1 (en) | 2002-03-21 | 2003-10-23 | Hirst Gavin C. | Kinase inhibitors |
| US7563798B2 (en) | 2002-09-04 | 2009-07-21 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| CA2512646A1 (en) | 2003-01-17 | 2004-08-05 | Warner-Lambert Company Llc | 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation |
| UA80763C2 (en) | 2003-05-22 | 2007-10-25 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | |
| GB0315966D0 (en) * | 2003-07-08 | 2003-08-13 | Cyclacel Ltd | Compounds |
| CN1835951B (zh) | 2003-07-11 | 2010-06-02 | 沃尼尔·朗伯有限责任公司 | 选择性cdk4抑制剂的羟乙基磺酸盐 |
| AU2004285052A1 (en) | 2003-10-31 | 2005-05-12 | Neurogen Corporation | 4-amino (AZA) quinoline derivatives as capsaicin receptor agonists |
| GB0329214D0 (en) | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Novel compounds |
| CA2555724A1 (en) | 2004-02-18 | 2005-09-09 | Warner-Lambert Company Llc | 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
| GB0403606D0 (en) | 2004-02-18 | 2004-03-24 | Novartis Ag | Organic compounds |
| ATE407119T1 (de) * | 2004-02-24 | 2008-09-15 | Glaxo Group Ltd | Pyridinderivate und deren verwendung als modulatoren des cb2-rezeptors |
| WO2005094830A1 (en) | 2004-03-30 | 2005-10-13 | Pfizer Products Inc. | Combinations of signal transduction inhibitors |
| MXPA06013250A (es) | 2004-05-14 | 2007-02-28 | Abbott Lab | Inhibidores de quinasa como agentes terapeuticos. |
| WO2005120509A1 (en) | 2004-06-04 | 2005-12-22 | Amphora Discovery Corporation | Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| BRPI0511065A (pt) | 2004-06-04 | 2007-12-26 | Pfizer Prod Inc | método para tratar crescimento de célula anormal |
| CA2575804A1 (en) | 2004-08-26 | 2006-03-02 | Boehringer Ingelheim International Gmbh | Pteridinones used as plk (polo like kinase) inhibitors |
| US7906528B2 (en) | 2004-10-05 | 2011-03-15 | Novartis International Pharmaceutical Ltd. | Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds |
| JP2008515982A (ja) | 2004-10-13 | 2008-05-15 | メルク エンド カムパニー インコーポレーテッド | 高眼圧症を治療するための眼科組成物 |
| US20060142312A1 (en) | 2004-12-23 | 2006-06-29 | Pfizer Inc | C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones |
| AU2006205851A1 (en) | 2005-01-14 | 2006-07-20 | Janssen Pharmaceutica N.V. | 5-membered annelated heterocyclic pyrimidines as kinase inhibitors |
| ES2552338T3 (es) | 2005-01-21 | 2015-11-27 | Astex Therapeutics Limited | Compuestos farmacéuticos |
| GB0501999D0 (en) * | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| WO2006131552A1 (de) | 2005-06-09 | 2006-12-14 | Boehringer Ingelheim International Gmbh | Alpha-carboline als cdk-1 inhibitoren |
| EP1931683B1 (en) | 2005-08-19 | 2011-07-13 | Schering Corporation | Fused tricyclic mglur1 antagonists as therapeutic agents |
| WO2007024680A1 (en) | 2005-08-22 | 2007-03-01 | Amgen Inc. | Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators |
| EP1942900B1 (en) | 2005-10-06 | 2015-06-03 | Merck Sharp & Dohme Corp. | Use of pyrazolo [1,5-a] pyrimidine derivatives for inhibiting kinases methods for inhibiting protein kinases |
| US7855194B2 (en) * | 2006-03-27 | 2010-12-21 | Hoffmann-La Roche Inc. | Pyrimidine, quinazoline, pteridine and triazine derivatives |
| US7763629B2 (en) | 2006-04-12 | 2010-07-27 | Vertex Pharmaceuticals Incorporated | Tetrahydropteridines useful as inhibitors of protein kinases |
| JP2009535393A (ja) | 2006-05-01 | 2009-10-01 | ファイザー・プロダクツ・インク | 置換２−アミノ縮合複素環式化合物 |
| EP2026805A1 (en) | 2006-05-08 | 2009-02-25 | Astex Therapeutics Limited | Pharmaceutical combinations of diazole derivatives for cancer treatment |
| US7893058B2 (en) | 2006-05-15 | 2011-02-22 | Janssen Pharmaceutica Nv | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
| US20070270362A1 (en) | 2006-05-18 | 2007-11-22 | The University Of Washington | Methods and compositions for prevention or treatment of inflammatory-related diseases and disorders |
| JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
| ATE510840T1 (de) | 2006-06-26 | 2011-06-15 | Ucb Pharma Sa | Kondensierte thiazol-derivate als kinasehemmer |
| MX2009002069A (es) | 2006-09-08 | 2009-03-06 | Pfizer Prod Inc | Sintesis de 2-(piridin-2-ilamino)pirido[2,3-d]pirimidin-7-onas. |
| AU2007301126A1 (en) * | 2006-09-28 | 2008-04-03 | Banyu Pharmaceutical Co., Ltd. | Diaryl ketimine derivative |
| WO2008076946A2 (en) | 2006-12-14 | 2008-06-26 | Panacea Pharmaceuticals, Inc. | Methods of neuroprotection by cyclin-dependent kinase inhibition |
| EP2134713A2 (en) | 2006-12-20 | 2009-12-23 | Schering Corporation | Novel jnk inhibitors |
| US20080234262A1 (en) | 2007-03-21 | 2008-09-25 | Wyeth | Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors |
| WO2009014642A1 (en) | 2007-07-19 | 2009-01-29 | Amgen Inc. | Combination of a de novo purine biosynthesis inhibitor and a cyclin dependent kinase inhibitor for the treatment of cancer |
| US7982035B2 (en) | 2007-08-27 | 2011-07-19 | Duquesne University Of The Holy Spirit | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof |
| US7960400B2 (en) | 2007-08-27 | 2011-06-14 | Duquesne University Of The Holy Ghost | Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof |
| US9259399B2 (en) | 2007-11-07 | 2016-02-16 | Cornell University | Targeting CDK4 and CDK6 in cancer therapy |
| EP2217611B1 (en) | 2007-11-07 | 2013-07-31 | Merck Sharp & Dohme Corp. | Novel modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors |
| AU2008343932B2 (en) | 2007-12-19 | 2013-08-15 | Amgen Inc. | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
| WO2009083780A1 (en) | 2007-12-28 | 2009-07-09 | Ipsogen | Breast cancer expresion profiling |
| AR070127A1 (es) | 2008-01-11 | 2010-03-17 | Novartis Ag | Pirrolo - pirimidinas y pirrolo -piridinas |
-
2009
- 2009-04-06 AT AT09730921T patent/ATE531372T1/de active
- 2009-04-06 WO PCT/US2009/039678 patent/WO2009126584A1/en not_active Ceased
- 2009-04-06 US US12/936,725 patent/US8389533B2/en active Active
- 2009-04-06 CA CA2719538A patent/CA2719538C/en not_active Expired - Fee Related
- 2009-04-06 MX MX2010010975A patent/MX2010010975A/es active IP Right Grant
- 2009-04-06 JP JP2011504114A patent/JP5530422B2/ja not_active Expired - Fee Related
- 2009-04-06 EP EP09730921A patent/EP2278973B1/en active Active
- 2009-04-06 AU AU2009233951A patent/AU2009233951B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011516558A5 (cg-RX-API-DMAC7.html) | ||
| JP6631616B2 (ja) | ＣＤＫ阻害剤としての２−アミノ−ピリド［２，３−ｄ］ピリミジン−７（８Ｈ）−オン誘導体及びその使用 | |
| CN117651700A (zh) | 2-氨基苯并噻唑化合物及使用方法 | |
| JP2024532735A (ja) | 複素環式化合物及び使用方法 | |
| US20240417412A1 (en) | Heterocyclic compounds and methods of use | |
| JP2015526394A5 (cg-RX-API-DMAC7.html) | ||
| JP2014506929A5 (cg-RX-API-DMAC7.html) | ||
| RU2019115115A (ru) | Производные пиперидина в качестве ингибиторов убиквитин-специфической протеазы 7 | |
| JP2016525092A5 (cg-RX-API-DMAC7.html) | ||
| JP2011500774A5 (cg-RX-API-DMAC7.html) | ||
| AU2008315048A1 (en) | Pyridone-substituted-dihydropyrazolopyrimidinone derivative | |
| AR119209A1 (es) | DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR | |
| WO2016015605A1 (en) | Compounds as cdk small-molecule inhibitors and uses thereof | |
| CA2998802A1 (en) | Fused pyrazole derivatives as kinase inhibitors | |
| JPWO2022232332A5 (cg-RX-API-DMAC7.html) | ||
| TW202423440A (zh) | Ｋｒａｓ ｇ１２ｃ突變蛋白的系鏈之雜環抑制劑及其用途 | |
| JP2024146897A5 (cg-RX-API-DMAC7.html) | ||
| AU2010218781A1 (en) | Pyrimidopyrimidoindazole derivative | |
| JPWO2022099117A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2019197842A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2019233457A5 (cg-RX-API-DMAC7.html) | ||
| WO2012098387A1 (en) | 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors | |
| WO2025217247A1 (en) | Tethered spiro-heterocyclic inhibitors of kras g12c mutant proteins and uses thereof | |
| WO2024133200A4 (en) | P2x3 receptor antagonists | |
| RU2023134860A (ru) | Ингибиторы мутации her2 |